Clinical Trials Logo
  1. Home
  2. Arthritis, Psoriatic
  3. NCT03828045

A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment — PREVAIL  

Arthritis, Psoriatic Clinical Trial

Official title:
Routine Clinical Practice in Spain: Evaluation of the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment (PREVAIL Study)

Clinical Trial Summary

Observational, prospective and multicenter study in approximately 25 sites nationwide. The investigators participating in this study will be rheumatologists specializing in this pathology. The study will include patients diagnosed with PsA (according to the CASPAR diagnosis criteria), naïve to biological treatments, who have - following the routine practice in their centers - initiated treatment with apremilast 6 months (±1 months) before their inclusion in the study, irrespective of treatment duration. Recruitment will be consecutive and the reason for not including a potential candidate patient will be registered. The decision to prescribe apremilast treatment should be clearly dissociated from the inclusion of the patient in the study, which will not occur earlier than 6 months (± 4 weeks after treatment start). Therefore, the choice of the therapeutic strategy will be made independently by the physician. Before entering the study, all patients shall sign an informed consent to participate in the study, including permission to retrieve data from their medical records and to complete questionnaires regarding their quality of life. To avoid recruitment biases and obtain a homogeneous cohort regarding treatment duration, all consecutive patients who attend to a routine follow-up visit and have been prescribed apremilast 6 months (+/- 4 weeks) before the baseline visit, will be offered to enter the study. All consecutive patients who can be contacted 6 months (+/- 4 weeks) following initiation of treatment with apremilast will be approached for entry to minimize bias in patient selection

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03828045
Study type Observational
Source Amgen
Contact
Status Completed
Phase
Start date February 6, 2019
Completion date October 20, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT02181673 - A Study of Golimumab in Participants With Active Psoriatic Arthritis Phase 3
Recruiting NCT04936308 - Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent Phase 3
Terminated NCT00090129 - Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis Phase 3
Withdrawn NCT03625089 - Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthritis N/A
Recruiting NCT05571696 - Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases N/A
Active, not recruiting NCT05071664 - A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis Phase 2
Completed NCT00938015 - Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis N/A
Suspended NCT03703934 - Central Pain Mechanisms in Patients With Hand-Osteoarthritis, Psoriatic Arthritis and Healthy Controls
Recruiting NCT05092269 - A Long-term Extension Study of Ustekinumab in Pediatric Participants Phase 3
Terminated NCT05083078 - A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis Phase 1
Completed NCT02436785 - Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? N/A
Completed NCT02294227 - 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis Phase 3
Completed NCT00998829 - Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis N/A
Completed NCT00760669 - An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants Phase 4
Completed NCT00367237 - Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) Phase 3
Completed NCT00051623 - A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis Phase 3
Withdrawn NCT04680676 - A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis Phase 2
Completed NCT03008590 - Low Dose Naltrexone for Chronic Pain From Arthritis Phase 2
Recruiting NCT05657847 - Novel Complex Radiodiagnostics of Peripherial Arthropathies
Completed NCT02875184 - A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands